Cutaneous lupus erythematosus (CLE) has gone more than 80 years without a newly approved therapy, and only 50% to 55% of patients respond adequately to antimalarials. Biologics directed at plasmacytoid dendritic cells (pDCs) are now producing responses in antimalarial-refractory disease, which deepen over a full year of treatment.
In this episode of ABCs in Dermatology, hosts Lindsay Ackerman, MD, of US Dermatology Partners, and Chris Bunick, MD, PhD, of Yale School of Medicine, reviewed 52-week AMETHYST Part A data for litifilimab. Among patients starting litifilimab at baseline, Cutaneous Lupus Activity Investigator's Global Assessment-Revised (CLA-IGA-R) erythema 0/1 responses rose from 19.0% at week 24 to 27.2% at week 52.1 Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 responses climbed from 21.7% to 28.8%.1
The phase 2 study randomized 93 adults refractory or intolerant to antimalarials and met its week 16 primary end point (14.7% vs 2.9% with placebo).1 The hosts highlighted CLASI-70 as a deliberately stringent bar, since CLASI-50 already tracks meaningful quality-of-life improvement. Nasopharyngitis, influenza, and arthralgia were the most common adverse events, with no serious viral infections through week 52.1
Litifilimab binds blood dendritic cell antigen 2 (BDCA2) on pDCs, curbing type I interferon production upstream of tissue inflammation.2,3 Anifrolumab (Saphnelo), approved for systemic lupus, instead blocks the type I interferon receptor downstream. The hosts likened the rising response curve to upstream interleukin 23 blockade in psoriasis, where responses build over time.
Patient-reported data presented at ACR Convergence 2026 echoed the clinician view. At week 24, 55.6% of litifilimab recipients were rated much or moderately better on the Clinician's Global Assessment of Skin vs 28.0% with placebo, and 48.9% vs 29.6% rated themselves this way.4 Complete clearance of morphologic features beyond erythema rose from 14.2% to 20.8% between weeks 24 and 52.4
Because roughly 80% of patients with CLE never progress to systemic lupus, the hosts argued dermatologists should own long-term care. Severity can be gauged by extent, high-impact sites such as the face, scalp, and hands, scarring risk, and treatment resistance. Acute CLE, renal warning signs, inflammatory musculoskeletal symptoms, new laboratory abnormalities, or multidrug-refractory disease should prompt rheumatology collaboration.
Phase 3 AMETHYST results are expected in the first half of 2027, alongside the LAVENDER trial of anifrolumab in a similar refractory population. Confirmation would give dermatology targeted, steroid-sparing options for a disease long managed with antimalarials and broad immunosuppression.
References
Merola JF, Werth V, Chong B, et al. Efficacy and safety of litifilimab in cutaneous lupus erythematosus (CLE): 52-week results of the phase 2 study, AMETHYST Part A. Abstract AS-1846. Presented at: European Academy of Dermatology and Venereology (EADV) Congress 2026; September 30-October 3, 2026; Vienna, Austria.
Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387(4):321-331. doi:10.1056/NEJMoa2118024
Furie R, Werth VP, Milliman E, et al. Pharmacodynamic effects of litifilimab in lupus in a randomized, placebo-controlled phase 2 study: rapid and sustained reductions in type I interferon-associated gene expression and cytokines. Arthritis Rheumatol. 2025;77(12):1726-1738. doi:10.1002/art.43271
[Authors and title to confirm.] AMETHYST Part A clinician- and patient-rated skin outcomes with litifilimab. Abstract 0872. Presented at: ACR Convergence 2026; November 8, 2026.